Kara Fine, MD
Endocrinology, Diabetes & Metabolism · Deerfield, ILNPI 1720286644
Payments from drug & device makers
Across 295 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$3K
- Abbott$569
- Novo Nordisk$546
- Sanofi-aventis U.S. LLC$316
- Ascensia Diabetes Care US Inc.$299
- Amgen$220
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$2103%
- Food & beverage$5,88697%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 75 | $2,641 |
| Abbott | 69 | $569 |
| Novo Nordisk | 38 | $546 |
| Sanofi-aventis U.S. LLC | 9 | $316 |
| Ascensia Diabetes Care US Inc. | 14 | $299 |
| Amgen(2 entities) | 8 | $220 |
| Antares Pharma, Inc. | 17 | $205 |
| AbbVie | 9 | $157 |
| Novartis | 5 | $128 |
| Tandem Diabetes Care, Inc. | 7 | $103 |
| Amneal Pharmaceuticals LLC | 5 | $98 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| AstraZeneca | 3 | $85 |
| Medtronic(2 entities) | 3 | $65 |
| Nevro Corp. | 2 | $46 |
| Corcept Therapeutics | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $32 |
| BD | 1 | $32 |
| Lilly USA, LLC | 1 | $29 |
| Insulet Corporation | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Mannkind Corporation | 1 | $25 |
| BETA Bionics, Inc. | 1 | $24 |
| Embecta Corp. | 1 | $23 |
| Bayer | 1 | $23 |
| Halozyme Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Cequr Corporation | 1 | $12 |
| Mission Pharmacal Company | 1 | $12 |
How this compares
$6,096 in reported general payments places this provider in the 75th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 315 | $511,918 |
| JardianceEmpagliflozin | 106 | $164,455 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 48 | $97,637 |
| MounjaroTirzepatide | 57 | $69,865 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $55,341 |
| FarxigaDapagliflozin Propanediol | 48 | $54,536 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $48,369 |
| JanuviaSitagliptin Phosphate | 46 | $47,147 |
| TrulicityDulaglutide | 31 | $43,847 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $35,328 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $26,345 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $25,567 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $20,215 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $18,509 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $18,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog | $546 | $634,977406 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $20 | $212,825138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $29 | $113,71288 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $316 | $55,34141 claims |
| AstraZenecaFarxiga | $85 | $54,53648 claims |
| AbbVieSynthroid | $157 | $2,97544 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $98 | $2,802253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Deerfield
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
- Ammar BayrakdarEvergreen Park$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.